Prognostic impact of dynamic changes of type I melanoma antigen gene proteins CT7 (MAGE-C1/CT7) transcripts in multiple myeloma
Type I melanoma antigen gene proteins CT7 (MAGE-C1/CT7), a cancer-testis (CT) gene, correlated with clinical parameters at diagnosis of multiple myeloma (MM). We first analyzed single-cell ribonucleic acid sequencing data from public databases to evaluate the expression of MAGE-C1/CT7 in MM patients...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1566265/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849312250717798400 |
|---|---|
| author | Xuelin Dou Fengrong Wang Huan Chen Yao Chen Lei Wen Yang Liu Guorui Ruan Xiaosu Zhao Xiaojun Huang Robert Peter Gale Jin Lu Jin Lu |
| author_facet | Xuelin Dou Fengrong Wang Huan Chen Yao Chen Lei Wen Yang Liu Guorui Ruan Xiaosu Zhao Xiaojun Huang Robert Peter Gale Jin Lu Jin Lu |
| author_sort | Xuelin Dou |
| collection | DOAJ |
| description | Type I melanoma antigen gene proteins CT7 (MAGE-C1/CT7), a cancer-testis (CT) gene, correlated with clinical parameters at diagnosis of multiple myeloma (MM). We first analyzed single-cell ribonucleic acid sequencing data from public databases to evaluate the expression of MAGE-C1/CT7 in MM patients and showed that MAGE-C1/CT7 is highly and specifically expressed in the MM cells. We then interrogated data from 216 consecutive cases with MAGE-C1/CT7 transcripts by quantitative real-time polymerase chain reaction longitudinally monitored in our center. The positive rate of MAGE-C1/CT7 at baseline was 87.3%, with a median level of 4.46% (0.01–939.5). In univariate Cox regression analysis, peri-ASCT MAGE-C1/CT7 status showed better discriminatory ability in PFS and survival than peri-ASCT multi-parameter flow-cytometry status assessed by flow cytometry. In multivariate analysis, patients who were MAGE-C1/CT7-negative pre-transplant and posttransplant had significantly better PFS than those who were positive in both determinations (HR = 0.33, 95% CI: 0.14, 0.80, p = 0.01). In 69 patients with informative samples, we found a 2-log decrease in MAGE-C1/CT7 transcript concentration after the second induction cycle correlated with achieving negative MAGE-C1/CT7-test results both pre-transplant and posttransplant (OR = 6.08, 95% CI: 1.78, 20.74, p = 0.004). Our data showed the predictive value of peri-ASCT frontline treatment. A 2-log decrease of MAGE-C1/CT7 post-induction cycle 2 compared to baseline correlated with a negative peri-ASCT MAGE-C1/CT7 status, providing an earlier prognostic marker of treatment response. |
| format | Article |
| id | doaj-art-9c2f09cc73394c4d98cf1827963ed0d4 |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-9c2f09cc73394c4d98cf1827963ed0d42025-08-20T03:53:07ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-05-011210.3389/fmed.2025.15662651566265Prognostic impact of dynamic changes of type I melanoma antigen gene proteins CT7 (MAGE-C1/CT7) transcripts in multiple myelomaXuelin Dou0Fengrong Wang1Huan Chen2Yao Chen3Lei Wen4Yang Liu5Guorui Ruan6Xiaosu Zhao7Xiaojun Huang8Robert Peter Gale9Jin Lu10Jin Lu11Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, ChinaPeking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, ChinaPeking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, ChinaPeking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, ChinaPeking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, ChinaPeking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, ChinaPeking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, ChinaPeking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, ChinaPeking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, ChinaCentre for Haematology, Department of Immunology and Inflammation, Imperial College of Science, Technology and Medicine, London, United KingdomPeking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, ChinaCollaborative Innovation Center of Hematology, Soochow University, Suzhou, ChinaType I melanoma antigen gene proteins CT7 (MAGE-C1/CT7), a cancer-testis (CT) gene, correlated with clinical parameters at diagnosis of multiple myeloma (MM). We first analyzed single-cell ribonucleic acid sequencing data from public databases to evaluate the expression of MAGE-C1/CT7 in MM patients and showed that MAGE-C1/CT7 is highly and specifically expressed in the MM cells. We then interrogated data from 216 consecutive cases with MAGE-C1/CT7 transcripts by quantitative real-time polymerase chain reaction longitudinally monitored in our center. The positive rate of MAGE-C1/CT7 at baseline was 87.3%, with a median level of 4.46% (0.01–939.5). In univariate Cox regression analysis, peri-ASCT MAGE-C1/CT7 status showed better discriminatory ability in PFS and survival than peri-ASCT multi-parameter flow-cytometry status assessed by flow cytometry. In multivariate analysis, patients who were MAGE-C1/CT7-negative pre-transplant and posttransplant had significantly better PFS than those who were positive in both determinations (HR = 0.33, 95% CI: 0.14, 0.80, p = 0.01). In 69 patients with informative samples, we found a 2-log decrease in MAGE-C1/CT7 transcript concentration after the second induction cycle correlated with achieving negative MAGE-C1/CT7-test results both pre-transplant and posttransplant (OR = 6.08, 95% CI: 1.78, 20.74, p = 0.004). Our data showed the predictive value of peri-ASCT frontline treatment. A 2-log decrease of MAGE-C1/CT7 post-induction cycle 2 compared to baseline correlated with a negative peri-ASCT MAGE-C1/CT7 status, providing an earlier prognostic marker of treatment response.https://www.frontiersin.org/articles/10.3389/fmed.2025.1566265/fullmultiple myelomaprognostic biomarkerMAGE-C1/CT7cancer testis antigen genesnovel agents |
| spellingShingle | Xuelin Dou Fengrong Wang Huan Chen Yao Chen Lei Wen Yang Liu Guorui Ruan Xiaosu Zhao Xiaojun Huang Robert Peter Gale Jin Lu Jin Lu Prognostic impact of dynamic changes of type I melanoma antigen gene proteins CT7 (MAGE-C1/CT7) transcripts in multiple myeloma Frontiers in Medicine multiple myeloma prognostic biomarker MAGE-C1/CT7 cancer testis antigen genes novel agents |
| title | Prognostic impact of dynamic changes of type I melanoma antigen gene proteins CT7 (MAGE-C1/CT7) transcripts in multiple myeloma |
| title_full | Prognostic impact of dynamic changes of type I melanoma antigen gene proteins CT7 (MAGE-C1/CT7) transcripts in multiple myeloma |
| title_fullStr | Prognostic impact of dynamic changes of type I melanoma antigen gene proteins CT7 (MAGE-C1/CT7) transcripts in multiple myeloma |
| title_full_unstemmed | Prognostic impact of dynamic changes of type I melanoma antigen gene proteins CT7 (MAGE-C1/CT7) transcripts in multiple myeloma |
| title_short | Prognostic impact of dynamic changes of type I melanoma antigen gene proteins CT7 (MAGE-C1/CT7) transcripts in multiple myeloma |
| title_sort | prognostic impact of dynamic changes of type i melanoma antigen gene proteins ct7 mage c1 ct7 transcripts in multiple myeloma |
| topic | multiple myeloma prognostic biomarker MAGE-C1/CT7 cancer testis antigen genes novel agents |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1566265/full |
| work_keys_str_mv | AT xuelindou prognosticimpactofdynamicchangesoftypeimelanomaantigengeneproteinsct7magec1ct7transcriptsinmultiplemyeloma AT fengrongwang prognosticimpactofdynamicchangesoftypeimelanomaantigengeneproteinsct7magec1ct7transcriptsinmultiplemyeloma AT huanchen prognosticimpactofdynamicchangesoftypeimelanomaantigengeneproteinsct7magec1ct7transcriptsinmultiplemyeloma AT yaochen prognosticimpactofdynamicchangesoftypeimelanomaantigengeneproteinsct7magec1ct7transcriptsinmultiplemyeloma AT leiwen prognosticimpactofdynamicchangesoftypeimelanomaantigengeneproteinsct7magec1ct7transcriptsinmultiplemyeloma AT yangliu prognosticimpactofdynamicchangesoftypeimelanomaantigengeneproteinsct7magec1ct7transcriptsinmultiplemyeloma AT guoruiruan prognosticimpactofdynamicchangesoftypeimelanomaantigengeneproteinsct7magec1ct7transcriptsinmultiplemyeloma AT xiaosuzhao prognosticimpactofdynamicchangesoftypeimelanomaantigengeneproteinsct7magec1ct7transcriptsinmultiplemyeloma AT xiaojunhuang prognosticimpactofdynamicchangesoftypeimelanomaantigengeneproteinsct7magec1ct7transcriptsinmultiplemyeloma AT robertpetergale prognosticimpactofdynamicchangesoftypeimelanomaantigengeneproteinsct7magec1ct7transcriptsinmultiplemyeloma AT jinlu prognosticimpactofdynamicchangesoftypeimelanomaantigengeneproteinsct7magec1ct7transcriptsinmultiplemyeloma AT jinlu prognosticimpactofdynamicchangesoftypeimelanomaantigengeneproteinsct7magec1ct7transcriptsinmultiplemyeloma |